# Fadi Kharouf

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fadi-kharouf/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,276 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 11 |
| i10-index | 12 |
| Last Known Institution | University of Toronto |
| OpenAlex ID | https://openalex.org/A5048407127 |
| ORCID iD | 0000-0002-3540-0341 |
| Works | 94 |

## Researcher papers

- [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study](https://scholariq.org/papers/immunogenicity-and-safety-of-the-bnt162b2-mrna-covid-19-vaccine-in-adult/)
- [LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma](https://scholariq.org/papers/lgr5-expressing-skin-fibroblasts-define-a-major-cellular-hub-perturbed-in/)
- [Autoimmune phenomena following SARS-CoV-2 vaccination](https://scholariq.org/papers/autoimmune-phenomena-following-sars-cov-2-vaccination/)
- [Advances in the management of psoriatic arthritis in adults](https://scholariq.org/papers/advances-in-the-management-of-psoriatic-arthritis-in-adults/)
- [Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study](https://scholariq.org/papers/immunogenicity-induced-by-two-and-three-doses-of-the-bnt162b2-mrna-vaccine-in/)
- [Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products](https://scholariq.org/papers/treatment-of-b-cell-depleted-covid-19-patients-with-convalescent-plasma-and/)
- [Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab](https://scholariq.org/papers/predictors-of-immunogenic-response-to-the-bnt162b2-mrna-covid-19-vaccination-in/)
- [IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations](https://scholariq.org/papers/il-1-inhibition-in-familial-mediterranean-fever-clinical-outcomes-and/)
- [Short- and long-term outcomes of patients with pure membranous lupus nephritis compared with patients with proliferative disease](https://scholariq.org/papers/short-and-long-term-outcomes-of-patients-with-pure-membranous-lupus-nephritis/)
- [Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience](https://scholariq.org/papers/increased-rates-of-idiopathic-inflammatory-myopathies-during-the-covid-19/)
- [Responsive and monophasic lupus nephritis: prevalence, associations and outcomes](https://scholariq.org/papers/responsive-and-monophasic-lupus-nephritis-prevalence-associations-and-outcomes/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)

## Researcher university

- [University of Toronto](https://scholariq.org/institutions/university-of-toronto/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.